Vestiage, Inc. (VEST: OTC Pink Current) | Vestiage Secures

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vestiage, Inc. (VEST: OTC Pink Current) | Vestiage Secures $10 Million in Advertising Funding from Media Funding Group

Vestiage™, Inc. (“VEST”), the “Healthy-Aging” Company, announced today that it has re-negotiated its agreement with Media Funding Group and secured an expanded commitment of $10 million in total media from Media Funding Group, a NWBB company. The funds will be made available immediately. Media Funding Group provides advertising expertise and private funding access for advertising and marketing campaigns.

“After getting more deeply involved with Vestiage, and seeing the growth in their commitments from national and other retailers, it made sense for Vestiage and Media Funding Group to structure a solution that covered both direct response advertising and supported the retail expansion and branding needs of RegiMEN™ and future brand launches,” said Marc Hatch, the Media Funding Group Vice President of Funding.

Scott Kimball, CEO of Vestiage, Inc. said, “We recently have experienced a swell in commitments from national and other retailers for the RegiMEN brand. In order to meet the changing media needs of our Company to support this expanding retail presence, we were able to secure an increase in the funding commitment from Media Funding Group that also covers brand and retail oriented advertising. Our RegiMEN television commercial is now entering production and we expect to begin airing it in August. In the meantime, we will continue to spend on national radio media.”

Vestiage sells RegiMEN in both the retail and direct-to-consumer channels. In the first quarter of 2014, the Company started its national radio campaign for the RegiMEN brand and saw strong initial acceptance from consumers as evidenced by an increase in gross revenue with both retail and direct response revenue growth contributing to the increase in sales. Additionally, the RegiMEN brand experienced good retention in monthly reorders. The Company is currently executing on a national retail rollout strategy that began February 3, 2014. RegiMEN is currently available at www.RegiMENLife.com and at select GNC and all Hi Health retail stores.

About Media Funding Group

Media Funding Group provides private funding access for Advertising and Marketing campaigns in exchange for a flexible blend of re-payment options including Equity Participation, Revenue Sharing or flexible payments on Revolving Credit Lines. For more information, please visit www.mediafundinggroup.com or call 1-360-835-1270.

About Vestiage™

Vestiage™ (stock symbol "VEST" ) is a publicly traded healthy aging company. The Company offers premium branded science-based nutraceuticals to a premium consumer base through multiple channels. The Company is a sales, marketing, and distribution company specializing in bringing science-based products to the healthy aging consumer. The Company utilizes key partners to integrate production, fulfillment, customer service, advertising, sales, media, marketing, distribution, new product development and acquisitions. Vestiage is focused on the use of the best ingredients from the ocean and earth, including cutting edge, patented, clinically proven ingredients to produce highly potent, and elegantly formulated products. Using potency and novel ingredient combinations, Vestiage™ creates and distributes nutraceuticals such as RegiMEN for men ( www.BuyRegimen.com ) and the multifunctional Monterey Bay Nutraceuticals line for women. ( www.MontereyBayNutra.com ). Vestiage™ brands address the top “in demand” healthy aging concerns of men and women. Vestiage™ research is focused on extending the active period of a human life covering both the cognitive and physical realms. To learn more, visit the Company website, www.vestiageinc.com .

As with many fast growing companies, our growth is dependent upon adequate funding for inventory, media, general overhead, professional fees, technology, salaries and other expenses related to the business. Should we be unable in the future to obtain appropriate funding to pay our expenses and media at current levels, our growth, and our financial stability, may be negatively impacted.

This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business. These forward looking statements can be identified by the use of terms such as "believe," "expects," "plan," "intend," "may," "will," "should," "can," or "anticipates," or the negative thereof, or variations thereon, or comparable terminology, or by discussions of strategy. These statements involve known and unknown risks, uncertainties and other factors that may cause industry trends or our actual results to be materially different from any future results expressed or implied by these statements. Important factors that may cause our results to differ from these forward-looking statements include, but are not limited to: (i) changes in or new government regulations or increased enforcement of the same, (ii) unavailability of desirable acquisitions or inability to complete them, (iii) increased costs, including from increased raw material or energy prices, (iv) changes in general worldwide economic or political conditions, (v) adverse publicity or negative consumer perception regarding nutritional supplements, anti-aging or stem cell facial care products or stem cell technology in general, (vi) issues with obtaining raw materials of adequate quality or quantity, (vii) litigation and claims, including product liability, intellectual property and other types, (viii) disruptions from or following acquisitions including the loss of customers, (ix) increased competition, (x) slow or negative growth in the anti-aging or cosmetics, beauty, or nutritional supplement industry or the healthy foods or anti-aging channel, (xi) the loss of key personnel or the inability to manage our operations efficiently, (xii) problems with information management systems, manufacturing efficiencies and operations, (xiii) insurance coverage issues, (xiv) the volatility of the stock market generally and of our stock specifically, (xv) increases in the cost of borrowings or unavailability of additional debt or equity capital, or both, or fluctuations in foreign currencies, and (xvi) interruption of business or negative impact on sales and earnings due to acts of God, acts of war, terrorism, bio-terrorism, civil unrest and other factors outside of our control.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

HD Hyundai Sparks Fusion Hopes with ITER Milestone

Updated Category News Views 9

Hold on to Your Hard Hats, Fusion Milestone Achieved Look who's making waves in the world of nuclear fusion. HD Hyundai Heavy Industries has hit a crucial benchmark in the ITER nuclear fusion project. This ain't your run-of-the-mill accomplishment, folks. We're talking about completing the assembly of some of the most complex and intricately designed machinery known to...

Continue Reading
ChemoMetec Boosts Financial Outlook with Anticipated Growth

Updated Category News Views 353

ChemoMetec Boosts Financial Outlook Amid Growing Interest ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches...

Continue Reading
GDS Holdings Completes Successful C-REIT IPO on Shanghai Exchange

Updated Category News Views 200

GDS Holdings Limited Celebrates C-REIT IPO Success GDS Holdings Limited, known as GDS, is thrilled to announce that it has successfully completed its initial public offering of its China REIT, or C-REIT, on the Shanghai Stock Exchange. This milestone marks an exciting moment for the company and its stakeholders as market interest surpassed expectations. Highlighting the...

Continue Reading
Innovative E-Waste Solutions from Techbros Redefine Recycling

Updated Category News Views 273

AI-Driven E-Waste Innovation from Techbros In a remarkable leap towards sustainability and innovative technology, Techbros Electronic Recycling proudly announces the launch of the Southwest's first fully integrated AI-driven IT asset disposition (ITAD) and e-waste processing facility. This state-of-the-art facility exemplifies the future of electronics recycling by...

Continue Reading
SageSure Welcomes Insurance Veteran Peter Hearn to Board

Updated Category News Views 268

SageSure Welcomes New Board Member SageSure, one of the largest managing general underwriters that focus on markets exposed to catastrophe risks, has taken a significant step by appointing Peter Hearn to its Board of Managers. This strategic move is anticipated to bolster the company’s leadership and industry insights. Peter Hearn's Impressive Background Peter Hearn...

Continue Reading